NPM1 mutations are identified in 5.4% of patients without concurrent “secondary-type” or TP53 mutations [8,30,52], suggesting that there is a non-random pattern of co-mutations with mutual exclusivity between TP53 and NPM1 mutations in t-AML. The gene discussed is NPM1; the disease is acute myeloid leukemia.